Cliff Asness’s AbCellera Biologics ABCL Stock Holding History

Cliff Asness’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-32,913	Closed	-$333K	–	2154
2022 Q4	$333K	Buy	+32,913	New	+$380K	﹤0.01%	1941

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's ABCL Position: Q1 2023 in Review

Cliff Asness sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 32,913 shares — an estimated $333K sold.

Cliff Asness first reported a position in ABCL in Q4 2022 and held it in 1 quarter. The position peaked at $333K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

Cliff Asness reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
Cliff Asness sold 32,913 AbCellera Biologics shares in Q1 2023, an estimated $333K.
Cliff Asness first reported a position in AbCellera Biologics in Q4 2022 and held it in 1 quarter.
Cliff Asness's AbCellera Biologics position peaked at $333K in Q4 2022.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on AQR Capital Management's 13F filing for Q1 2023, filed 15 May 2023.